echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The cost of the new vaccine was priced, the semi-annual report was released, and Consino's market value fell by $7.7 billion.

    The cost of the new vaccine was priced, the semi-annual report was released, and Consino's market value fell by $7.7 billion.

    • Last Update: 2020-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: the opening of the vaccine sector fell across the board, but because of the "new crown vaccine cost price" was misread! On August 23rd Concino, a biopharmaceutical company listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange, reported its first-half results.
    first half of the year revenue of 4.03 million yuan, a year-on-year increase of 1.9 million yuan.
    net profit attributable to the parent company was negative 102 million yuan, an increase of 46.65 percent over the same period, mainly due to the continued research and development of vaccines and clinical trials, research and development spending is higher.
    August 23, according to media reports, the National Health And Wellness Commission Science and Technology Development Center Director, the State Council joint prevention and control mechanism of scientific research team vaccine research and development team leader Zheng Zhongwei in CCTV Finance broadcast the "dialogue" column revealed that the new crown vaccine can only be based on cost as a pricing basis.
    Vaccines fell across the board, but not "cost pricing" pot may be precisely because of the impact of the above news, this morning, Concino once fell more than 13%, the vaccine sector fell across the board, Zhifei Bio fell 9%, Junzheng Group, Kantai Bio fell 7%, Watson Bio continued to weaken, as of the close of the stock market, the concept of heat has rebounded, Zhifei Bio fell 2.81%, Kantai Bio fell 2.94%, Watson Bio fell 2.97%.
    news of the cost of the new crown vaccine, in particular, has killed all hope for the many investors who have been calling Consino "the first stock of the new crown".
    actually refer to the ebola virus sales path, the new crown vaccine is so positioned is the most reasonable situation.
    to make money from the "new crown vaccine", not only will the country not agree, the whole country will not agree.
    The National Vaccine Administration Law also clearly stipulates that in the event of a particularly significant public health event, the National Health and Health Commission shall apply for emergency use of the vaccine, and the National Drug Administration shall organize experts to demonstrate and agree that the National Health and Safety Commission shall make emergency use of the vaccine within a certain scope and within a certain time limit.
    but not all vaccines choose cost pricing, and the internet's claim that "future vaccines will rely on cost pricing" is either misreading or ulterior motives.
    consecutive years of losses, but does not affect any confidence in investment as an innovative vaccine company, indeed the research and development pipeline includes the prevention of Ebola virus disease, meningitis, new coronavirus (COVID-19), white crack, pneumonia, tuberculosis, shingles and other clinically in greater demand vaccine varieties.
    , however, a big hard injury is that no vaccine has been brought to market, and the corresponding revenue is impossible to talk about.
    4.03 million yuan in the first half of the year, mainly from vaccine parts sales and technical services revenue.
    the fifth set of standards in the board's listing review rules does not require profitability, it may be more that Concino's data on these fronts play a role.
    will continue to face high-intensity research and development investments until vaccine products are brought to market.
    first half of this year, Consino invested 108 million yuan in research and development, which translates into a large loss in the financial report.
    in the first half of this year, Concino realized a loss of 102 million yuan attributable to shareholders of listed companies, and a loss attributable to shareholders of listed companies of 116 million yuan, excluding non-recurring gains and losses, largely due to huge expenditures on vaccine research and development and clinical trials.
    's balance sheet is 19.50 per cent lower than its peers, below Chifei Bio (49.93 per cent), Changchun Gaoxin (30.66 per cent), Wantay Bio (24.13 per cent), and higher than Watson Bio (16.07 per cent) and Hualan Bio (12.42 per cent), according to the current financial report.
    Commercialized products are the most closely watched than the recombinant new coronavirus vaccine (adenovirus vector), but Concino still in the semi-annual report on the risk factors, that is, recombinant new coronavirus vaccine (adenovirus vector) there is a risk of research and development failure and non-commercialization.
    includes the risk of research and development failure, market sales risk, the risk that capacity will not meet market demand, and the risk that the new crown outbreak will end before the vaccine is successfully developed and large-scale commercial sales will not be achieved.
    , the meningitis vaccine is also highly expected by Concino.
    , Concino and Pfizer reached a cooperation agreement to jointly bring the four-price meningococcal-binding vaccine to the Chinese market in the future.
    meningococcal-binding vaccines MCV4 and MCV2 vaccines have also been submitted to the Drug Administration for listing.
    , MCV2 submitted for registration and acceptance of new drugs in February 2019, and MCV4 submitted for registration and acceptance of new drugs in November 2019 and was included in the priority review.
    predict that the two vaccines are expected to be available this year and next, and that it will take time to test whether they can be called "potentially China's best vaccine" and "potentially China's first vaccine".
    Valuation If you refer to huada gene from 260 to 50 past events, combined with the current capital market enthusiasm for the vaccine industry, coupled with the market performance of Concino in recent days, rumors of overpricing of Concino, it may quite be possible, it is expected that in the next period of time, Concino's share price may continue to fluctuate.
    All in all, in the short term, Concino's share price may face a downward trend; Recommended reading: 1. The latest version of the new coronary treatment program released: Lianhua Qing plague, musk positive gas, blood must be clean, hot poison Ning... 2. WHO investigates Russia's first new crown vaccine, group immunization is so simple! 3. Consino is listed! A sign to earn 150,000 dream why a day on the "break" 4.200 yuan a needle imported drugs sold 700,000! Netizens: Why isn't life-saving drugs covered by zero tariffs and health insurance? 5. Fosun Pharma has gone up and down, or because of the exclusive "SARS-COV-2 vaccine" in the Chinese market.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.